EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Circulating tumour DNA as a promising biomarker for breast cancer diagnosis & treatment monitoring

Riddhi Ursekar, Rohan Chaubal, Khushboo A Gandhi, Elizabeth Talker, Jaya Chitra, Aishwarya Raja, Rushikesh Sunil Mukhare, Ankita Singh, Anushree Kadam, Mrudula Madhav, Shwetali Pandey, Sudeep Gupta

The Indian Journal of Medical Research · 23.04.2025 · 161 · 267-277

DOI: 10.25259/ijmr_1291_2024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Indian Journal of Medical Research, online erschienen am 23.04.2025. Verfasst von Riddhi Ursekar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Genomics and Hypoxia Lab (Clinician Scientist Laboratory), Advanced Centre for Treatment, Research, and Education in Cancer, Tata Memorial C…. Hauptthemen laut MEDLINE: Breast Neoplasms, Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer contributes a large fraction to mortality among women diagnosed with cancer. It is important to monitor residual disease and extend the lead time to detect relapse in high-risk patients. Minimally invasive techniques that utilise circulating biomarkers are being explored for their potential in diagnosis, prognosis, and disease monitoring of breast cancer. Circulating biomarkers have been investigated as tools for breast cancer diagnosis, prognosis, prediction, and monitoring of therapeutic response and resistance. Among these, circulating tumour cells and cell-free plasma DNA (cfDNA) derived from tumour cells (circulating tumour DNA i.e . ctDNA) have been integrated into clinical trial designs. Among all circulating biomarkers, ctDNA stands out as a promising biomaterial with great potential as it is thought to mirror the tumour’s evolution. However, its clinical utilisation is hampered mainly by gaps in knowledge of its biological properties and specific characteristics. The development of robust and standardised methods for assessing circulating biomarkers is essential for realising the potential of personalised medicine. This review aims to summarise the characteristics of ctDNA and its role in breast cancer, drawing from both basic and translational research to provide insights into its clinical application. This review suggests that ctDNA has the potential to be a non-invasive, real-time surrogate for tumour tissue-based biomarkers. In conclusion, circulating biomarkers have the potential to revolutionise breast cancer diagnosis, prognosis, and treatment monitoring, but the development of standardised methods for their assessment is essential. ctDNA, in particular, shows great promise as a liquid biopsy tool, but further research is needed to understand its biology and ensure its clinical utility fully.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCirculating Tumor DNABiomarkers, TumorHumansFemalePrognosisNeoplastic Cells, Circulating

Stichwörter der Autor:innen

Biomarkersbreast cancercell free DNAcirculating tumour DNAdiagnosisliquid biopsy

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Clinical Genomics and Hypoxia Lab (Clinician Scientist Laboratory), Advanced Centre for Treatment, Research, and Education in Cancer, Tata Memorial Centre, Mumbai, Maharashtra, India.
  • Homi Bhabha National Institute, Training School Complex, Mumbai, Maharashtra, India.
  • Department of Surgical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, Maharashtra, India.
  • Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, Maharashtra, India.

Zitieren

APA

Ursekar, R., Chaubal, R., Gandhi, K. A., Talker, E., Chitra, J., Raja, A., Mukhare, R. S., Singh, A., Kadam, A., Madhav, M., Pandey, S., & Gupta, S. (2025). Circulating tumour DNA as a promising biomarker for breast cancer diagnosis & treatment monitoring. The Indian Journal of Medical Research, 161, 267-277. https://doi.org/10.25259/ijmr_1291_2024

Vancouver

Ursekar R, Chaubal R, Gandhi KA, Talker E, Chitra J, Raja A, et al. Circulating tumour DNA as a promising biomarker for breast cancer diagnosis & treatment monitoring. The Indian Journal of Medical Research. 2025;161:267-277. doi:10.25259/ijmr_1291_2024

BibTeX
@article{Ursekar2025,
  author = {Ursekar, Riddhi and Chaubal, Rohan and Gandhi, Khushboo A and Talker, Elizabeth and Chitra, Jaya and Raja, Aishwarya and Mukhare, Rushikesh Sunil and Singh, Ankita and Kadam, Anushree and Madhav, Mrudula and Pandey, Shwetali and Gupta, Sudeep},
  title = {Circulating tumour DNA as a promising biomarker for breast cancer diagnosis & treatment monitoring},
  journal = {The Indian Journal of Medical Research},
  year = {2025},
  volume = {161},
  pages = {267--277},
  doi = {10.25259/ijmr_1291_2024}
}
Kostenlos starten →